Overview

Exploratory Study of DHA in Systemic Lupus Erythematosus Patients

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the efficacy of DHA in patients with SLE.
Phase:
Phase 2
Details
Lead Sponsor:
Kunming Pharmaceuticals, Inc.
Treatments:
Artemisinins
Artenimol
Dihydroartemisinin